Shots:

• The company has completed the enrollment in the P-IIB HOPE4MCI trial evaluating the efficacy of AGB101 vs PBO in 164 patients to treat amnestic mild cognitive impairment due to AD across 23 sites in the US and Canada
• The HOPE4MCI study followed an earlier study that showed a reduction in hippocampal overactivity and improvement in episodic memory. The HOPE4MCI study will evaluate cognitive and functional efficacy as measured by CDR-SB- MMSE- FAQ
• The HOPE4MCI trial also includes a sub-study of brain PET imaging to measures neurodegeneration. The results of the study are expected in Nov’2022

  Ref: PRNewswire | Image: Pharmaceutical Report